Business Context and Reporting Period
This Form 8-K was filed by Kura Oncology, Inc. on September 13, 2024. The report discloses a corporate governance event involving the appointment of a new director and the associated compensatory arrangements.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on director compensation details:
- Annual Cash Retainer: $40,000 for Board service.
- Committee Retainer: $7,500 for Compensation Committee service.
- Initial Equity Grant: Options to purchase 52,000 shares (vesting annually over three years) and 17,333 shares (vesting in full after one year).
- Future Equity Grants: Automatic annual options for 26,000 shares on the date of each annual meeting.
Material Changes
On September 13, 2024, the Board appointed Michael J. Vasconcelles, M.D., as a Class III director with a term expiring at the 2026 annual meeting. He was also appointed as a member of the Compensation Committee. No other material financial or operational changes were reported in this filing.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding business operations. The only risk-related disclosure notes that the option grants vest in full in the event of a change in control, as defined in the Company's Amended and Restated 2014 Equity Incentive Plan.
Key Facts for Investor Verification
- Verify the total number of outstanding shares and the dilution impact of the 69,333 initial option grants and future annual grants.
- Confirm the vesting schedule details for the 52,000 shares (three-year annual vesting) versus the 17,333 shares (one-year cliff vesting).
- Review the Company's Amended and Restated Non-Employee Director Compensation Policy to understand the annual compensation limits referenced in the filing.
- Check for any subsequent filings regarding Dr. Vasconcelles' background or potential conflicts of interest, though the filing states none exist under Item 404(a).